Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens
Overview
Affiliations
Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.
Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment.
Martinez-Sobrido L, Nogales A Int J Mol Sci. 2024; 25(19).
PMID: 39408912 PMC: 11476892. DOI: 10.3390/ijms251910584.
Lieber C, Aggarwal M, Yoon J, Cox R, Kang H, Sourimant J PLoS Pathog. 2023; 19(4):e1011342.
PMID: 37068076 PMC: 10138230. DOI: 10.1371/journal.ppat.1011342.
Treatment of Respiratory Viral Coinfections.
Alexander P, Dobrovolny H Epidemiologia (Basel). 2022; 3(1):81-96.
PMID: 36417269 PMC: 9620919. DOI: 10.3390/epidemiologia3010008.
Sourimant J, Lieber C, Yoon J, Toots M, Govindarajan M, Udumula V Sci Adv. 2022; 8(25):eabo2236.
PMID: 35749502 PMC: 9232112. DOI: 10.1126/sciadv.abo2236.
Bu L, Chen B, Xing L, Cai X, Liang S, Zhang L Front Cell Infect Microbiol. 2022; 11:827790.
PMID: 35127568 PMC: 8811159. DOI: 10.3389/fcimb.2021.827790.